Breast cancer treatment methods have improved significantly, increasing patient survival rates. However, cardiovascular diseases are now the main cause of death in oncological patients, as cardiovascular complications caused by commonly used oncological treatments are a significant issue. Anthracyclines are incorporated into schemes of breast cancer (BC) chemotherapeutic treatment: HER2-positive, HER2-negative, and triple-negative BC subtypes, but the cardiotoxicity they cause needs to be taken into consideration. If a patient experiences this complication, heart failure is treated with pharmacological intervention following the European Society of Cardiology guidelines. A 38-year-old woman’s case highlights the complexity of making treatment decisions in this group of patients because she developed heart failurewith reduced left ventricular ejection fraction due to chemotherapy treatment.

W artykule przedstawiono przypadek pacjenta z nieresekcyjnym rakiem żołądka, u którego zastosowano tislelizumab. Po około roku od włączenia leczenia wystąpił ostry zespół wieńcowy. Przypadek pokazuje, że przed zastosowaniem tislelizumabu warto ocenić całkowite ryzyko sercowo-naczyniowe chorego.

Hypertrophic cardiomyopathy (HCM) is characterized by the presence of left ventricular hypertrophy (LVH) that cannot be explained by atypical loading conditions. This case report describes a 67-year-old female patient with hypertension and dyslipidemia who presented with dyspnea, chest pain, and a history of syncope. Initial echocardiography suggested LVH secondary to hypertension. However, further evaluation revealed asymmetrical LVH with significant left ventricular outflow tract obstruction (LVOTO), suggesting HCM, which was confirmed in cardiac magnetic resonance imaging and genetic testing. Despite maximal medical therapy, the patient remained symptomatic and was subsequently treated with mavacamten. This case highlights the challenges in diagnosing HCM, particularly in patients with comorbidities, and discusses the evolving role of pharmacological treatment in LVOTO management.

The significant causes of chest pain, a common symptom in general practice, include myocardial infarction (MI), including cases caused by coronary artery dissection, as well as psychogenic pain. A 54-year-old female patient presented to her family doctor in the morning with a 2-hour history of nausea and chest pain. Physical examination revealed elevated blood pressure and heart rate of 80 beats per minute. She was a low cardiovascular risk patient, with a history of anxiety disorders and recurrent chest pain of neurotic origin. The electrocardiography (ECG) showed an ST-segment depression in leads V4 and V5. Echocardiography (USG) revealed hypokinesia of the mid-segment of the lateral wall. Coronary angiography showed a 90% distal obstruction of the intermediate branch of the left coronary artery, caused by a vessel dissection with an intramural hematoma, with preserved blood flow. Antihypertensive and cholesterol-lowering medications were initiated. To date, the patient does not report any chest pain. It is necessary to perform a thorough diagnostic work-up including an ECG in patients presenting with chest pain, even if previous chest pain episodes were attributed to anxiety disorders.